Search

Your search keyword '"Joshua J. Reading"' showing total 2 results
Start Over Author "Joshua J. Reading" Topic mass spectrometry
2 results on '"Joshua J. Reading"'

1. Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens

Author

Jeffrey R. Whiteaker, Rachel A. Lundeen, Lei Zhao, Regine M. Schoenherr, Aura Burian, Dongqing Huang, Ulianna Voytovich, Tao Wang, Jacob J. Kennedy, Richard G. Ivey, Chenwei Lin, Oscar D. Murillo, Travis D. Lorentzen, Mathangi Thiagarajan, Simona Colantonio, Tessa W. Caceres, Rhonda R. Roberts, Joseph G. Knotts, Joshua J. Reading, Jan A. Kaczmarczyk, Christopher W. Richardson, Sandra S. Garcia-Buntley, William Bocik, Stephen M. Hewitt, Karen E. Murray, Nhan Do, Mary Brophy, Stephen W. Wilz, Hongbo Yu, Samuel Ajjarapu, Emily Boja, Tara Hiltke, Henry Rodriguez, and Amanda G. Paulovich

Subjects
immunotherapy, cancer, correlative biomarkers, mass spectrometry, immuno-MRM, Immunologic diseases. Allergy, RC581-607
Abstract

Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of immunomodulatory proteins in the tumor microenvironment shape the anti-tumor response, few of them can be reliably quantified. To address this need, we developed a multiplex panel of targeted proteomic assays targeting 52 peptides representing 46 proteins using peptide immunoaffinity enrichment coupled to multiple reaction monitoring-mass spectrometry. We validated the assays in tissue and plasma matrices, where performance figures of merit showed over 3 orders of dynamic range and median inter-day CVs of 5.2% (tissue) and 21% (plasma). A feasibility study in clinical biospecimens showed detection of 48/52 peptides in frozen tissue and 38/52 peptides in plasma. The assays are publicly available as a resource for the research community.

Published
2021
Full Text
View/download PDF

2. Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens

Author

Rhonda R. Roberts, Christopher W. Richardson, Aura Burian, Lei Zhao, Karen E. Murray, Regine M. Schoenherr, Amanda G. Paulovich, Sandra S. Garcia-Buntley, Jan Kaczmarczyk, Oscar Murillo, Mathangi Thiagarajan, Richard G. Ivey, Emily S. Boja, Rachel A. Lundeen, Samuel Ajjarapu, Ulianna Voytovich, Hongbo Yu, Chenwei Lin, Tessa W. Caceres, Jacob J. Kennedy, William Bocik, Tara Hiltke, Joshua J. Reading, Henry Rodriguez, Stephen M. Hewitt, Nhan Do, Stephen W. Wilz, Dongqing Huang, Simona Colantonio, Mary Brophy, Jeffrey R. Whiteaker, Joseph G. Knotts, Travis D. Lorentzen, and Tao Wang

Subjects
Proteomics, Proteome, medicine.medical_treatment, Blotting, Western, Immunology, Peptide, Computational biology, Antibodies, Mass Spectrometry, Specimen Handling, Jurkat Cells, correlative biomarkers, Research community, Cell Line, Tumor, Methods, Medicine, Immunology and Allergy, Humans, cancer, Multiplex, RNA-Seq, Frozen tissue, chemistry.chemical_classification, Tumor microenvironment, business.industry, Cancer, Reproducibility of Results, Immunotherapy, RC581-607, medicine.disease, immuno-MRM, Targeted mass spectrometry, chemistry, MCF-7 Cells, immunotherapy, Immunologic diseases. Allergy, business, Peptides, Chromatography, Liquid, HeLa Cells
Abstract

Immunotherapies are revolutionizing cancer care, producing durable responses and potentially cures in a subset of patients. However, response rates are low for most tumors, grade 3/4 toxicities are not uncommon, and our current understanding of tumor immunobiology is incomplete. While hundreds of immunomodulatory proteins in the tumor microenvironment shape the anti-tumor response, few of them can be reliably quantified. To address this need, we developed a multiplex panel of targeted proteomic assays targeting 52 peptides representing 46 proteins using peptide immunoaffinity enrichment coupled to multiple reaction monitoring-mass spectrometry. We validated the assays in tissue and plasma matrices, where performance figures of merit showed over 3 orders of dynamic range and median inter-day CVs of 5.2% (tissue) and 21% (plasma). A feasibility study in clinical biospecimens showed detection of 48/52 peptides in frozen tissue and 38/52 peptides in plasma. The assays are publicly available as a resource for the research community.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results